[go: up one dir, main page]

CL2012001752A1 - Compuestos derivados de triazolopiridina, moduladores de sistema hgf/cmet; composicion farmaceutica que lo comprende; y su uso en el tratamiento del cancer. - Google Patents

Compuestos derivados de triazolopiridina, moduladores de sistema hgf/cmet; composicion farmaceutica que lo comprende; y su uso en el tratamiento del cancer.

Info

Publication number
CL2012001752A1
CL2012001752A1 CL2012001752A CL2012001752A CL2012001752A1 CL 2012001752 A1 CL2012001752 A1 CL 2012001752A1 CL 2012001752 A CL2012001752 A CL 2012001752A CL 2012001752 A CL2012001752 A CL 2012001752A CL 2012001752 A1 CL2012001752 A1 CL 2012001752A1
Authority
CL
Chile
Prior art keywords
triazolopyridine
cmet
hgf
cancer
treatment
Prior art date
Application number
CL2012001752A
Other languages
English (en)
Inventor
Wei-Guo Su
Hong Jia
Guangxiu Dai
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001752(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of CL2012001752A1 publication Critical patent/CL2012001752A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos derivados de triazolopiridina y triazolopirazina, moduladores del sistema HGF/cMet; composiciones farmacéuticas; y un método para tratar un cáncer sensible a la inhibición de c-Met.
CL2012001752A 2009-12-31 2012-06-26 Compuestos derivados de triazolopiridina, moduladores de sistema hgf/cmet; composicion farmaceutica que lo comprende; y su uso en el tratamiento del cancer. CL2012001752A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31

Publications (1)

Publication Number Publication Date
CL2012001752A1 true CL2012001752A1 (es) 2013-01-25

Family

ID=44226181

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001752A CL2012001752A1 (es) 2009-12-31 2012-06-26 Compuestos derivados de triazolopiridina, moduladores de sistema hgf/cmet; composicion farmaceutica que lo comprende; y su uso en el tratamiento del cancer.

Country Status (38)

Country Link
US (9) US8987269B2 (es)
EP (5) EP3795573B1 (es)
JP (5) JP5337313B2 (es)
KR (3) KR101771299B1 (es)
CN (3) CN106117248B (es)
AU (2) AU2010338712B2 (es)
BR (1) BR112012016129B1 (es)
CA (1) CA2785749C (es)
CL (1) CL2012001752A1 (es)
CO (1) CO6612235A2 (es)
CU (1) CU24167B1 (es)
CY (2) CY1118250T1 (es)
DK (3) DK2719699T3 (es)
DO (1) DOP2012000188A (es)
EA (2) EA030141B1 (es)
EC (1) ECSP12012011A (es)
ES (4) ES2927146T3 (es)
GT (1) GT201200220A (es)
HR (3) HRP20221090T1 (es)
HU (3) HUE052828T2 (es)
IL (2) IL220433B (es)
LT (1) LT3795573T (es)
ME (1) ME02211B (es)
MX (2) MX386852B (es)
MY (1) MY179933A (es)
NI (1) NI201200118A (es)
NZ (1) NZ601128A (es)
PE (3) PE20130375A1 (es)
PH (1) PH12012501355A1 (es)
PL (3) PL2719699T3 (es)
PT (3) PT3795573T (es)
RS (3) RS54217B1 (es)
SG (1) SG181781A1 (es)
SI (2) SI3511330T1 (es)
SM (3) SMT202200371T1 (es)
UA (1) UA107822C2 (es)
WO (1) WO2011079804A1 (es)
ZA (1) ZA201205730B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2927146T3 (es) * 2009-12-31 2022-11-02 Hutchison Medipharma Ltd Ciertas triazolopirazinas, composiciones de estas y sus métodos de empleo
DK2571878T3 (en) 2010-05-17 2019-02-11 Indian Incozen Therapeutics Pvt Ltd Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
CN107082779A (zh) * 2012-03-30 2017-08-22 理森制药股份公司 作为c‑met 蛋白激酶调节剂的新化合物
CA2776178A1 (en) 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
EP2944637B1 (en) 2013-01-11 2020-02-19 FUJIFILM Corporation Nitrogen-containing heterocylic compound or salt thereof
BR112015020787B1 (pt) 2013-03-06 2022-12-06 Astrazeneca Ab Compostos 4-(substituído-anilino)-6-o-(substituídopiperizina-carbonil)quinazolínicos, seus sais, composição farmacêutica, uso e combinação
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
ES2675355T3 (es) * 2013-09-30 2018-07-10 Korea Research Institute Of Chemical Technology Derivados de triazolopirazina como inhibidores de tirosina cinasa
DK3087070T3 (en) * 2013-12-26 2017-12-04 Ignyta Inc PYRAZOLO [1,5-A] PYRIDINE DERIVATIVES AND PROCEDURES FOR THEIR USE
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
CN109400613B (zh) * 2015-12-31 2021-05-07 上海医药集团股份有限公司 喹啉类化合物富马酸盐的晶型、制备方法、组合物与应用
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160889A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
MX2021002640A (es) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
CA3110762A1 (en) * 2018-09-11 2020-03-19 Astrazeneca Ab Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
AU2019346464A1 (en) 2018-09-25 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
EP3873905A4 (en) 2018-10-30 2022-08-17 Repare Therapeutics Inc. COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING COMPOUNDS AND THEIR USE AS ATR KINASE INHIBITORS
WO2020124060A1 (en) 2018-12-14 2020-06-18 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof
CA3123583A1 (en) 2018-12-17 2020-06-25 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
BR112021018456A2 (pt) 2019-03-22 2021-11-23 Achillion Pharmaceuticals Inc Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
CA3148278A1 (en) * 2019-07-22 2021-01-28 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
JP2023515073A (ja) * 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
IL301146A (en) * 2020-09-28 2023-05-01 Codexis Inc Engineered biocatalysts and methods for synthesizing chiral amines
EP4263523A2 (en) * 2020-12-16 2023-10-25 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
KR102659095B1 (ko) 2021-01-08 2024-04-19 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
CA3248309A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. γ-AMINOBUTYRIC ACID RECEPTOR MODULATOR SALTS, PARTICLES AND THEIR USES
CA3261476A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Combination with HGF Receptor Inhibitors for the Treatment of Cancer
AU2023312919A1 (en) * 2022-07-29 2025-03-06 Baylor College Of Medicine Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法
WO2024148089A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Cdk2 inhibitors
GB202300923D0 (en) 2023-01-20 2023-03-08 Macfarlan Smith Ltd Novel polymorphic forms of savolitinib
WO2024263860A1 (en) * 2023-06-22 2024-12-26 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP1082324A4 (en) * 1998-05-26 2002-01-02 Merck & Co Inc IMIDAZOPYRIDINE COMPOUNDS AS THROMBINE INHIBITORS
JP2000119250A (ja) * 1998-08-11 2000-04-25 Takeda Chem Ind Ltd 環状アミド化合物、その製造法、中間体及び除草剤
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
JP2007516180A (ja) * 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
AU2004274403A1 (en) 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
US7361763B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006018735A2 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
SI1853602T1 (sl) * 2005-02-16 2010-11-30 Astrazeneca Ab Kemične spojine
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
WO2007075567A1 (en) * 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines as tyrosine kinase modulators
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
NZ575548A (en) 2006-09-18 2011-09-30 Vertex Pharma Heterocyclic inhibitors of c-Met and uses thereof
EP2081937B1 (en) * 2006-10-23 2012-09-12 SGX Pharmaceuticals, Inc. Triazolopyridazine protein kinase modulators
EA200970403A1 (ru) 2006-10-23 2009-10-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Бициклические триазолы в качестве модуляторов протеинкиназы
JP5572388B2 (ja) 2006-11-22 2014-08-13 インサイト・コーポレイション キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MX2009010984A (es) 2007-04-10 2010-01-15 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
WO2008138842A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
EP2285216A4 (en) * 2008-02-21 2012-09-19 Sequoia Pharmaceuticals Inc HIV PROTEASE INHIBITOR AND COMBINED CYTOCHROME P450 INHIBITOR
PE20091468A1 (es) 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
ES2376404T3 (es) 2008-05-22 2012-03-13 Amgen Inc. Heterociclos como inhibidores de proteínas cinasas.
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
EA201200260A1 (ru) * 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
EA201200318A1 (ru) * 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
ES2927146T3 (es) * 2009-12-31 2022-11-02 Hutchison Medipharma Ltd Ciertas triazolopirazinas, composiciones de estas y sus métodos de empleo
DK2571878T3 (en) 2010-05-17 2019-02-11 Indian Incozen Therapeutics Pvt Ltd Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES

Also Published As

Publication number Publication date
KR20170098324A (ko) 2017-08-29
EP2519524A1 (en) 2012-11-07
HUE052828T2 (hu) 2021-05-28
US20180263977A1 (en) 2018-09-20
CN106117248B (zh) 2019-01-22
HRP20150952T1 (hr) 2015-10-09
CU20120101A7 (es) 2012-10-15
SMT202000693T1 (it) 2021-01-05
EP2719699A1 (en) 2014-04-16
NZ601128A (en) 2014-12-24
US10512645B2 (en) 2019-12-24
JP2018009004A (ja) 2018-01-18
CN102906092B (zh) 2016-08-03
KR101905350B1 (ko) 2018-11-30
EA025466B1 (ru) 2016-12-30
EP3795573A1 (en) 2021-03-24
IL239997A (en) 2017-11-30
ES2726152T3 (es) 2019-10-02
HUE025504T2 (en) 2016-02-29
JP6194046B2 (ja) 2017-09-06
RS61281B1 (sr) 2021-02-26
US20120264739A1 (en) 2012-10-18
DK3511330T3 (da) 2020-12-21
US10946014B2 (en) 2021-03-16
CY1118250T1 (el) 2017-06-28
DK2719699T3 (en) 2015-08-24
CN106432225A (zh) 2017-02-22
EP3511330A1 (en) 2019-07-17
US20240139182A1 (en) 2024-05-02
EP2966075B1 (en) 2019-02-27
CY1123777T1 (el) 2022-03-24
CN106432225B (zh) 2019-02-19
CN106117248A (zh) 2016-11-16
PE20160588A1 (es) 2016-07-09
SMT201500213B (it) 2015-10-30
IL239997A0 (en) 2015-08-31
JP6647434B2 (ja) 2020-02-14
SI2719699T1 (sl) 2015-12-31
AU2010338712A1 (en) 2012-07-12
SG181781A1 (en) 2012-07-30
CO6612235A2 (es) 2013-02-01
RS54217B1 (sr) 2015-12-31
WO2011079804A1 (en) 2011-07-07
AU2015203480B2 (en) 2017-10-26
KR101434766B1 (ko) 2014-08-26
PT2719699E (pt) 2015-09-30
PH12012501355A1 (en) 2012-12-17
MX2012007756A (es) 2012-11-06
ES2927146T3 (es) 2022-11-02
US8987269B2 (en) 2015-03-24
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
ME02211B (me) 2016-02-20
ECSP12012011A (es) 2012-10-30
HK1194071A1 (en) 2014-10-10
JP2013209418A (ja) 2013-10-10
JP2013516393A (ja) 2013-05-13
DOP2012000188A (es) 2012-12-31
ES2840454T3 (es) 2021-07-06
US20200179377A1 (en) 2020-06-11
CA2785749A1 (en) 2011-07-07
PL2719699T3 (pl) 2016-01-29
EA030141B1 (ru) 2018-06-29
EA201200951A1 (ru) 2013-09-30
MX336996B (es) 2016-02-09
US20210154192A1 (en) 2021-05-27
JP5337313B2 (ja) 2013-11-06
PT3795573T (pt) 2022-09-15
LT3795573T (lt) 2022-11-10
KR20120125261A (ko) 2012-11-14
CU24167B1 (es) 2016-03-31
EP3795573B1 (en) 2022-07-06
RS63612B1 (sr) 2022-10-31
US8507487B2 (en) 2013-08-13
EA201691461A1 (ru) 2017-01-30
SI3511330T1 (sl) 2021-01-29
HRP20221090T1 (hr) 2022-11-25
AU2015203480A1 (en) 2015-07-16
ZA201205730B (en) 2016-01-27
JP2019108345A (ja) 2019-07-04
SMT202200371T1 (it) 2022-11-18
BR112012016129A2 (pt) 2016-05-31
JP6486999B2 (ja) 2019-03-20
BR112012016129B1 (pt) 2020-11-03
US20120245178A1 (en) 2012-09-27
MX386852B (es) 2025-03-19
HUE059696T2 (hu) 2022-12-28
ES2546635T3 (es) 2015-09-25
CA2785749C (en) 2017-11-28
IL220433B (en) 2018-01-31
UA107822C2 (xx) 2015-02-25
PL3511330T3 (pl) 2021-04-19
DK3795573T3 (da) 2022-09-19
EP2966075A1 (en) 2016-01-13
EP2719699B1 (en) 2015-07-08
PE20130375A1 (es) 2013-04-10
PT3511330T (pt) 2020-12-24
EP3511330B1 (en) 2020-09-30
MY179933A (en) 2020-11-19
KR20140059307A (ko) 2014-05-15
US11896592B2 (en) 2024-02-13
US9956218B2 (en) 2018-05-01
US20250099462A1 (en) 2025-03-27
CN102906092A (zh) 2013-01-30
AU2010338712B2 (en) 2015-04-02
US20150368271A1 (en) 2015-12-24
PL3795573T3 (pl) 2022-11-21
US20170027934A1 (en) 2017-02-02
KR101771299B1 (ko) 2017-08-24
EP2519524A4 (en) 2013-07-03
JP2016155848A (ja) 2016-09-01
GT201200220A (es) 2014-12-22
HRP20202017T1 (hr) 2021-02-19
HK1216880A1 (en) 2016-12-09

Similar Documents

Publication Publication Date Title
CL2012001752A1 (es) Compuestos derivados de triazolopiridina, moduladores de sistema hgf/cmet; composicion farmaceutica que lo comprende; y su uso en el tratamiento del cancer.
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
CL2008003188A1 (es) Compuestos derivados de piridina y pirazina; composicion farmaceutica que los comprende;y su uso en el tratamiento o prevencion de tumores sensibles a la inhibicion de enzimas del receptor ax1 y/o c-met.
CL2007000311A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CR20120202A (es) Métodos y composiciones para tratar cáncer
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CL2015000897A1 (es) Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer.
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.